Aptarion biotech
Business Services · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Max-dohrn-straße 8 10, Berlin, Berlin, 1...Phone Number
+49 30959982133Website
www.aptarion.comRevenue
<$5 MillionIndustry
About Aptarion biotech
Is Aptarion biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Aptarion biotech has new funding data
Check out if Aptarion biotech is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Aptarion biotech has recently received funding, and reach out quickly before it becomes old news!
Aptarion biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Aptarion biotech recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Aptarion biotech
Product Launch: Get notified when Aptarion biotech launches new products
Click to see if Aptarion biotech had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Aptarion biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aptarion biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aptarion biotech.
Aptarion biotech Tech Stack
A closer look at the technologies used by Aptarion biotech
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Aptarion biotech
Aptarion Biotech AG specializes in developing innovative drugs for life-threatening diseases, utilizing the unique properties of mirror-image L-aptamers. Their lead drug candidate, AON-D21, is currently undergoing a Phase 2 clinical trial involving 150 patients with severe community-acquired pneumonia across five European countries and the USA. The... Read More